Polypharmaceutical Breeding

Polypharmaceutical breeding refers to intentional selection strategies aimed at developing cannabis cultivars with diverse cannabinoid and terpene profiles—rather than single-compound dominance. Breeders working in this category often cross varieties with complementary chemical signatures to create plants that express multiple minor cannabinoids (CBG, CBC, CBDV) alongside primary cannabinoids like THC or CBD. This approach is rooted in the cannabis entourage hypothesis, which posits that complex plant chemistry may function synergistically. Polypharmaceutical lines are frequently documented in research contexts and breeding programs focused on phytochemical complexity rather than potency alone. These cultivars require careful phenotype selection and multi-generational stabilization to maintain consistent minor-cannabinoid expression.

Breeders pursuing polypharmaceutical profiles typically employ analytical testing (HPLC, GC-MS) during selection to map cannabinoid and terpene ratios across offspring. This data-driven approach enables targeted crosses that preserve or amplify rare minor cannabinoids while maintaining robust plant vigor.